A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
Public ClinicalTrials.gov record NCT00478634. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Multicenter Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab (if Given as Part of Local Standard Practice) in Patient With Metastatic Colorectal Adenocarcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will assess the safety of RAD001 when given together with cetuximab and irinotecan
Study identification
- NCT ID
- NCT00478634
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 19 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2007 (Type not available)
- Primary completion
- Sep 2009 (Actual)
- Completion
- Sep 2009 (Actual)
- Last update posted
- Nov 2, 2012
2007 – 2009
United States locations
- U.S. sites
- 16
- U.S. states
- 11
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Highlands Oncology Group | Fayetteville | Arkansas | 72701 | — |
| Comprehensive nBlood and Cancer Care | Bakersfield | California | 93309 | — |
| UCSD - Moores Cancer Center | La Jolla | California | 92037 | — |
| Comprehensive Cancer Care | Los Angeles | California | 90095 | — |
| North Valley Hematology/Oncology Medical Group: The Thomas & Dorothy Leavey Cancer Center | Northridge | California | 91325 | — |
| Cancer Care Associates Medical Group, Inc. | Redondo Beach | California | 90277 | — |
| Norwalk Hospital | Norwalk | Connecticut | 06850 | — |
| Gerogetown University Lombardi Cancer Center | Washington D.C. | District of Columbia | 20057 | — |
| H. Lee Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Oncology Specialists | Park Ridge | Illinois | 60068 | — |
| Nevada Cancer Institute | Las Vegas | Nevada | 89135 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Richmond University Medical Center | Staten Island | New York | 10310 | — |
| UNC School of Medicine | Chapel Hill | North Carolina | 27599 | — |
| Oncology/Hematology Associates | Bethlehem | Pennsylvania | 18017 | — |
| Arlington Cancer Center | Arlington | Texas | 76012 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00478634, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 2, 2012 · Synced Oct 31, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00478634 live on ClinicalTrials.gov.